A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

References

• Melton 3rd LJ. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003;32:1–13
   PubMed Web of Science ®Google Scholar
• Tuck SP, Francis RM. Osteoporosis. Postgrad Med J 2002;78: 526–32
   PubMed Web of Science ®Google Scholar
• US Congress OoTA. Hip fracture outcomes in people aged fifty and over [online]. Available from http://www.wws.princeton.%20edu/cgi-bin/byteserv.prl/~ota/disk1/1994/9413/9413.PDF [May 10, 2005]
   Google Scholar
• Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis? Ann Intern Med 1986;104: 817–23
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878–82
   PubMed Web of Science ®Google Scholar
• Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study [Study of Osteoporotic Fractures Research Group]. Arch Intern Med 1999;159:1215–20
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–39
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Assoc 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Chevalley T, Hoffmeyer P, Bonjour JP, et al. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporosis Int 2002;13:450–5
   PubMed Web of Science ®Google Scholar
• Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103:S20–S25
   Google Scholar
• Body JJ. Management of primary osteoporosis. Acta Clin Belg 2002;57:277–83
   PubMed Web of Science ®Google Scholar
• Boonen S, Vanderschueren D. Fracture protection in osteoporosis with risedronate. Hosp Med 2004;65:535–40
   PubMed Web of Science ®Google Scholar
• Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Rozkydal Z, Janicek P. The effect of alendronate in the treatment of postmenopausal osteoporosis. Bratisl Lek Listy 2003;104:309–13
   PubMedGoogle Scholar
• Sartori L, Adami S, Filipponi P, et al. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res 2003;15:271–83
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349: 1207–15
   PubMed Web of Science ®Google Scholar
• Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int 2002;13:644–9
   PubMed Web of Science ®Google Scholar
• Stephen AB, Wallace WA. The management of osteoporosis. J Bone Jt Surg Br 2001;83:316–23
   PubMedGoogle Scholar
• Cole RP, Palushock S, Haboubi A. Osteoporosis management: physicians’ recommendations and womens’ compliance following osteoporosis testing. Women Health 1999;29:101–15
   Google Scholar
• Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
   PubMedGoogle Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis [The Alendronate Phase III Osteoporosis Treatment Study Group]. New Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617–24
   PubMed Web of Science ®Google Scholar
• Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis [Alendronate Osteoporosis Treatment Study Groups]. J Am Med Assoc 1997;277:1159–64
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporosis Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women [Hip Intervention Program Study Group]. New Engl J Med 2001;344:333–40
   PubMed Web of Science ®Google Scholar
• Eichner SF, Lloyd KB, Timpe EM. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 2003;37:711–24
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859–62
   Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 2003;14:259–62
   Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Sunyecz J, Gallagher R, MacCosbe P. Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. The Female Patient 2006;31:21–8
   Google Scholar
• Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006;17:922–8
   PubMed Web of Science ®Google Scholar
• Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80: 856–61
   Google Scholar
• Sebaldt RJ, Shane LG, Pham B, et al. Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporosis Int 2004;15: S107
   Web of Science ®Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• Finigan J, Bainbridge P, Eastell R. Adherence to osteoporosis therapies. Osteoporosis Int 2001;12:[abstract P.110]
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Managed Care Pharm 2004;10:142–51
   Google Scholar
• Watts NB. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 2001;16:S407
   Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74: 129–35
   PubMed Web of Science ®Google Scholar
• Schiff I, Rebar R, Cramer J, et al. Achieving long-term continuance of menopausal ERT/HRT: Consensus Opinion of the North American Menopause Society. Menopause 1998;5: 69–76
   PubMed Web of Science ®Google Scholar
• Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12: 7–15
   PubMed Web of Science ®Google Scholar
• Prestwood KM. Osteoporosis: up-to-date strategies for prevention and treatment [Interview by Marc E. Weksler]. Geriatrics 1997;52:92–4, 7–8
   Google Scholar
• Gallagher JC. Pathophysiology of osteoporosis. Semin Nephrol 1992;12:109–15
   PubMed Web of Science ®Google Scholar
• Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporosis Int 2004;15:695–700
   PubMed Web of Science ®Google Scholar
• Liel Y, Castel H, Bonneh DY. Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low-impact fractures. Osteoporosis Int 2003;14:490–5
   Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117–23
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
   Google Scholar
• Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006;12:522–8
   Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–16
   PubMed Web of Science ®Google Scholar
• Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814–23
   PubMed Web of Science ®Google Scholar
• Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074–90
   PubMed Web of Science ®Google Scholar